Article
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Expert review of hematology - 1 Dec 2017
Luskin Marlise R, DeAngelo Daniel J
Abstract excerpt
INTRODUCTION: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with inadequate treatment options. Approximately one-third of cases have a FLT3-ITD or FLT3-TKD mutation which leads to constitutive tyrosine kinase activation which contributes to leukemogenesis. The FLT3-ITD mutation is associated with a particularly poor prognosis. Midostaurin is a multi-kinase inhibitor active against the FLT3...
Topics
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Cell Transformation, Neoplastic
- Drug Approval
- Drug Resistance, Neoplasm
- Humans
- Leukemia, Myeloid, Acute
- Molecular Targeted Therapy
- Mutation
- Prognosis